A prospective randomised controlled trial assessing the efficacy of Pegatanib sodium (Macugen) in the prevention of proliferative diabetic retinopathy.

Trial Profile

A prospective randomised controlled trial assessing the efficacy of Pegatanib sodium (Macugen) in the prevention of proliferative diabetic retinopathy.

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Mar 2014

At a glance

  • Drugs Pegaptanib (Primary)
  • Indications Diabetic retinopathy
  • Focus Therapeutic Use
  • Acronyms EPPPDR
  • Most Recent Events

    • 14 Jul 2012 New source identified and integrated (European Clinical Trials Database record EudraCT2007-006795-10).
    • 14 Jul 2011 Last checked against United Kingdom Clinical Research Network.
    • 02 Jan 2011 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top